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Abstract
Summary We aimed to establish jump power cut-offs for the composite outcome of either sarcopenia (EWGSOP2) or
dysmobility syndrome using Asian and Caucasian cohorts. Estimated cut-offs were sex specific (women: < 19.0 W/kg; men:
< 23.8 W/kg) but not ethnicity specific. Jump power has potential to be used in definitions of poor musculoskeletal health.
Purpose Weight-corrected jump power measured during a countermovement jump may be a useful tool to identify individuals
with poor musculoskeletal health, but no cut-off values exist.We aimed to establish jump power cut-offs for detecting individuals
with either sarcopenia or dysmobility syndrome.
Methods Age- and sex-matched community-dwelling older adults from two cohorts (University of Wisconsin-Madison [UW],
Korean Urban Rural Elderly cohort [KURE], 1:2) were analyzed. Jump power cut-offs for the composite outcome of either
sarcopenia defined by EWGSOP2 or dysmobility syndrome were determined.
Results The UW (n = 95) and KURE (n = 190) cohorts were similar in age (mean 75 years) and sex distribution (68% women).
Jump power was similar between KURE and UWwomen (19.7 vs. 18.6W/kg, p = 0.096) and slightly higher in KURE than UW
in men (26.9 vs. 24.8 W/kg, p = 0.050). In UW and KURE, the prevalence of sarcopenia (7.4% in both), dysmobility syndrome
(31.6% and 27.9%), or composite of either sarcopenia or dysmobility syndrome (32.6% and 28.4%) were comparable. Low jump
power cut-offs for the composite outcome differed by sex but not by ethnicity (< 19.0W/kg in women; < 23.8W/kg in men). Low
jump power was associated with elevated odds of sarcopenia (adjusted odds ratio [aOR] 4.07), dysmobility syndrome (aOR
4.32), or the composite of sarcopenia or dysmobility syndrome (aOR 4.67, p < 0.01 for all) independent of age, sex, height, and
ethnicity.
Conclusion Sex-specific jump power cut-offs were found to detect the presence of either sarcopenia or dysmobility syndrome in
older adults independent of Asian or Caucasian ethnicity.
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Introduction
Sarcopenia, the age-related loss of muscle mass and function,
is recognized as an important geriatric syndrome leading to
negative health outcomes such as falls, fractures, hospitaliza-
tions with increased medical costs, and mortality [1–5]. Until
recently, low muscle mass was required to diagnose
sarcopenia as a core component, despite evidence suggesting
muscle function as an independent and more sensitive indica-
tor for aging and health outcomes [3, 6–8]. Taking this into
consideration, the EuropeanWorking Group on Sarcopenia in
Older People (EWGSOP) proposed a new algorithm with the
emphasis on screening for sarcopenia in individuals with low
muscle function rather than muscle mass [3]. As a more com-
prehensive approach, dysmobility syndrome was previously
proposed to identify older individuals with high risk of falls,
fractures, and decreased mobility [4, 9, 10]. Similar to meta-
bolic syndrome, dysmobility syndrome is diagnosed when
several components are present together including previous
falls, low muscle function, poor physical performance, low
appendicular lean mass, high fat mass, and low bone mass
[10, 11]. In Caucasian and Asian middle-aged to elderly co-
horts, dysmobility syndrome is associated with decreased
physical activity and increased risk for falls, fractures, and
mortality [12–16].
Establishing a diagnostic threshold for muscle function test-
ing with good discriminatory ability is important for the identi-
fication of individuals with sarcopenia or dysmobility syn-
drome. Currently, the most commonly used muscle function
tests in sarcopenia definitions are usual gait speed and grip
strength [3, 4, 6, 17, 18]. Both usual gait speed and grip strength
have proven their usefulness in large epidemiologic studies but
have limitations in a given individual including larger variabil-
ity, not testing maximal effort (and therefore having a ceiling
effect), being impacted by comorbidities and testing maximal
force rather than power [4, 6, 17, 19]. Muscle function tests that
do not have these limitations may have the potential to improve
diagnostic performance for identifying individuals with
sarcopenia or dysmobility syndrome and also monitoring dis-
ease progression or response to treatment over time. Jump pow-
er, measured during a two-legged countermovement jump, has
been utilized to assess muscle function in various populations
including older adults with impaired function [20–28]. The
countermovement jump combines maximal effort during an ex-
plosive movement (i.e., high power output) with the require-
ment for good coordination of various muscle and joint groups,
and organ systems required for balance [4, 19, 20]. It combines
features of classical muscle function tests like grip strength
(maximal effort) with classical physical function tests like usual
gait speed (requirement for a high degree of coordination of
different organ systems), with good safety and reproducibility
[4, 20, 21, 28, 29]. Low jump power is associated with
sarcopenia or dysmobility syndrome in older Caucasian or
Asian adults [24, 30, 31]. However, to our knowledge, interna-
tional cut-offs for weight-corrected jump power to identify indi-
viduals with either sarcopenia or dysmobility syndrome across
different ethnic groups have not been investigated. The aim of
this study was to explore the cut-offs for weight-corrected jump
power that could be used internationally to identify individuals
with sarcopenia or dysmobility syndrome using a combined
cohort of Caucasian and Asian older adults.
Methods
Cohorts
For this analysis, we combined cohorts of older community-
dwelling individuals with two different ethnic backgrounds
(Asian and Caucasian) in whom data on muscle mass and
function were available.
Korean urban rural elderly cohort (South Korea)
The KURE study is a prospective, longitudinal cohort study
investigating health and aging of community-based older
adults in Korea. A total of 3517 individuals residing in three
urban districts and one rural area were recruited from 2012 to
2015 via random visits, local government health facilities, or
promotional posters. Further details of the KURE protocol can
be found elsewhere [32, 33]. This study was approved by the
Severance Hospital Ethics Committee (IRB No. 4–2012-
0172). Because jumping mechanography and bioimpedance
analysis (BIA) testing were added to the standard study pro-
tocol of KURE in 2014, only participants recruited in 2014
and 2015 (1493 subjects) were included in this study. All
participants underwent anthropometric analysis, interviewer-
assisted questionnaires, laboratory assessments, and dual-
energy x-ray absorptiometry (DXA, QDR 4500A; Hologic,
USA) for bone mineral density measurements according to
standardized protocols. Appendicular lean mass was estimat-
ed through BIA (InBody720; Biospace Co., Ltd., Seoul,
Korea). All participants were asked to perform muscle func-
tion tests including timed get-up-and-go, grip strength, and
two-legged jumping on a computerized ground force plate.
Because 4-m gait speed testing was added to the standard
examination protocol in the middle of the follow-up phase
(2018), estimated gait speed was calculated from timed get-
up-and-go results using conversion equation derived from an
internal dataset (KURE dataset 2018, n = 605; gait speed
[m/s] = 4/[timed get-up-and-go performance (second) ×
0.360 + 0.146]; Supplementary Fig. 1). Those who had active
inflammatory status with elevated high-sensitivity c-reactive
protein (> 8 mg/L) or leukocytosis (white blood cell count >
15,000 cells/mm3; n = 51), current malignancy (n = 54),
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refused or failed to jump (n = 126), or any missing value in
study variables were excluded from this analysis (Fig. 1).
University of Wisconsin-Madison cohorts (United States Of
America)
Three hundred eighty-one individuals with weight-corrected
jump power data from four different studies performed at the
University of Wisconsin-Madison were included. Details
about each study have been previously published [29,
34–36]. In brief, all studies recruited community-dwelling
adults in the Midwestern United States (Wisconsin). All stud-
ies were cross-sectional and three of them only recruited older
adults. In these three studies, exclusion criteria included recent
(within the last 6 months) cardiovascular events, major sur-
gery, severe end-organ disease, history of malignancy with
metastasis to the musculoskeletal system, and neuromuscular
disease impairing balance to the degree of being unable to
stand without assistance. Less than 2% of participants who
met these criteria were not able to perform a valid jump. In
all studies, appendicular lean mass was measured by DXA
using a GE/Lunar iDXA densitometer (Madison, WI, USA).
Beside jump power, muscle function tests included grip
strength and the short physical performance battery (SPPB)
combining usual gait speed, 5-chair-rise-time, and balance
assessment. All studies were approved by the local ethics
committee. Participants younger than 65 years of age and
those with missing data points were excluded (see Fig. 1).
Jump power measurements
All participants in both KURE and UW cohorts were asked to
perform two-legged countermovement jumps on a computerized
ground force plate using established protocols [37]. Equipment,
software (Leonardo version 4.2; Novotec, Pforzheim, Germany),
and jumping protocols were identical in both cohorts. In brief,
participants were asked to perform three two-leg countermove-
ment jumps with standardized instruction to jump as high as
possible. There were no restrictions on arm movement. Jump
power is the product of force and velocity. Velocity is calculated
through integration of acceleration over time. The jump with the
maximal height was chosen for analysis, and peak, weight-
corrected jump power (jump power/body weight, W/kg) was
recorded. Individuals who refused to jump due to fear of falls,
dizziness, or recent surgery on joints or who could not actually
leave the ground were excluded from the analysis. No adverse
events such as falls or traumawere observed during the testing in
either cohort. Jump power measurement showed excellent repro-
ducibility (intraclass correlation coefficient 0.93) without short-
term learning effect in our prior work [38].
Study outcomes
Sarcopenia
Sarcopenia was defined by the revised consensus of European
Working Group on Sarcopenia in Older People (EWGSOP2).
Fig. 1 Study flow. KURE, Korean Urban Rural Elderly cohort; UW, University of Wisconsin-Madison cohort
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As the initial step, individuals with low grip strength (< 27 kg
in men and < 16 kg in women) or low five-times chair rise test
performance (15 s or higher) were diagnosed as having “prob-
able sarcopenia.” Sarcopenia was “confirmed” when individ-
uals with “probable sarcopenia” had low lean mass. Cut-offs
for low leanmass in Caucasian and Asian cohorts were chosen
based on regional normative populations according to the
EWGSOP2 guideline. In the Caucasian cohort (UW), low
lean mass was defined based on the normative reference from
an Australian cohort (DXA-based ALM/height2 < 7.0 kg/m2
in men and < 5.5 kg/m2 in women), which was the recom-
mended cut-off by EWGSOP2 guideline for Europeans [3, 17,
39]. For the Asian cohort (KURE), low lean mass was defined
by recommended cut-off from Asian Working Group for
Sarcopenia guideline (BIA-based ALM/height2 < 7.0 kg/m2
in men; ALM/height2 < 5.7 kg/m2 in women) [40].
Dysmobility syndrome
In the Caucasian cohorts (UW), dysmobility syndrome was
defined according to the criteria suggested by Binkley and
colleagues [9]. The following six parameters were included
in this dysmobility syndrome definition: history of one of
more falls within last 12 months, slow gait speed (<
1.0 m/s), low grip strength (< 30 kg in men; < 20 kg in wom-
en), low appendicular lean mass (DXA-based ALM/height2 <
7.26 kg/m2 in men; < 5.45 kg/m2 in women), high fat mass
(percent body fat > 30% in men; > 40% in women), and oste-
oporosis (BMD T score ≤ − 2.5 at lumbar spine, femoral neck,
or total hip). Each included factor was equally weighted (1
point per risk factor), and the presence of three or more factors
was defined as having dysmobility syndrome. In the Asian
cohort (KURE), the same criteria were applied, with the ex-
ception of different cut-offs for low lean mass (BIA-based
ALM/height2 < 7.0 kg/m2 in men; ALM/height2 < 5.7 kg/m2
in women) and low grip strength (< 26 kg in men; < 18 kg in
women) based on regional reference endorsed by AWGS
criteria [40].
Composite outcome of sarcopenia or dysmobility syndrome
The composite outcome of the presence of either sarcopenia or
dysmobility syndrome was defined as the primary outcome to
establish a practical cut-off for jump power that could be ap-
plied internationally.
Statistics
Data are presented as mean ± SD or as numbers (percentages)
as appropriate. Because KURE and UW cohorts showed sig-
nificantly heterogeneous age distribution with higher mean
age in UW (Supplementary Fig. 2A; 80.4 ± 6.3 vs. 71.4 ±
4.3, p < 0.001), sex-stratified age matching with the range (±
3 years) was performed with an 1:2 ratio (UW:KURE) to
minimize the possibility of confounding from differences in
age distribution in addition to differences in ethnicity. After
matching, similar distribution of age was observed between
two cohorts (Fig. 1; Supplementary Fig. 2B; mean age 74.9 ±
3.9 vs. 75.3 ± 3.7, p = 0.373). Clinical characteristics of par-
ticipants in matched cohorts were compared using indepen-
dent t test for continuous variables or chi-squared tests for
categorical variables. The relationship between weight-
corrected jump power and age were plotted based on a pre-
diction from linear regression as grouped by sex and ethnicity.
Diagnostic cut-offs of low jump power yielding best binary
classification for the composite outcome of sarcopenia
(EWGSOP2) or dysmobility syndrome were estimated at the
point value that maximizes the Liu index (sensitivity × speci-
ficity) on a receiver-operating characteristic (ROC) curve in
groups stratified by the combination of sex and ethnicity [41].
As a sensitivity analysis, cut-offs were also estimated by
Youden method as another ROC-based cut-off estimation al-
gorithm (finding a cutoff that maximizes sensitivity + speci-
ficity − 1). As cut-offs derived by both methods were largely
dependent on sex but not by ethnicity, we decided to use
identical cut-offs for KURE and UW participants within
the same sex strata. Crude or adjusted odds ratios for
sarcopenia, dysmobility syndrome, and the composite out-
come of sarcopenia or dysmobility syndrome were calculated
separately using multiple logistic regression models. Areas
under the receiver-operating characteristics curve (AUC) were
compared to quantify the improvement in discriminatory abil-
ity by low jump power when added to age, sex, height, and
ethnicity. All analyses were performed by STATA 14.2
(College Station, TX, USA). The level of statistical signifi-
cance was set at a two-sided p < 0.05.
Results
Study demographics
Mean age (75.0 ± 3.9 years overall; 74.9 in KURE vs. 75.3 in
UW, p = 0.372) and proportion of women (68.4%) did not
differ between age-matched KURE and UW cohorts
(Table 1). Individuals in the UW cohort had a higher mean
BMI (26.7 vs. 23.8 kg/m2, p < 0.001). Weight-corrected jump
power was similar between Caucasian and Asian cohorts in
women and slightly higher in Asian cohort in men (KURE vs.
UW; 19.7 vs. 18.6 W/kg in women, p = 0.096; 26.9 vs.
24.8 W/kg in men, p = 0.050). The prevalence of sarcopenia
(EWGSOP2), dysmobility syndrome, and the composite out-
come in combined cohorts were 7.4%, 29.1%, and 30.9%,
respectively, and did not differ between UW and KURE
(prevalence of sarcopenia 7.4% in both, dysmobility syn-
drome 31.6% and 27.9%, and composite of either sarcopenia
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or dysmobility syndrome 32.6% and 30.0%, respectively).
Among the six components of dysmobility syndrome, UW
participants were more likely to have higher prevalence of
high fat mass compared with KURE participants, whereas
KURE participants had higher prevalence of slow gait speed
and osteoporosis (Table 1). Weight-corrected jump power
showed weak correlations with grip strength (r = 0.37 and
0.33 in men and women, respectively; Supplementary Fig. 3).
Relationship of jump power and age
There was a negative linear correlation between weight-
corrected jump power and age in both men and women
(Supplementary Fig. 4). Per 5-year increment in age, weight-
corrected jump power was reduced by 2.0 W/kg (95% CI 3.4
to − 0.6, p = 0.005) and by 1.5W/kg (95%CI 2.5 to − 0.5, p =
0.003) in men and women, respectively. No significant inter-
action between age and ethnicity was observed (p for interac-
tion = 0.915 in men; p for interaction = 0.201 in women).
When vertical jump power was normalized by a lean mass
index (appendicular lean mass/height2, W/kg/m2), the fitted
values for age of the two cohorts aligned more closely and
without a signif icant difference in mean values
(Supplementary Fig. 5; UW vs. KURE: 265 vs. 269 W/kg/
m2 in men, p = 0.733; 202 vs. 206 W/kg/m2 in women, p =
0.609).
Jump power cut-off for the composite outcome
The sex-specific weight-corrected jump power cut-offs for the
presence of either sarcopenia or dysmobility syndrome (the
composite outcome) were estimated to find the point value
that maximizes the binary discriminatory performance for
each sex and ethnic group combination (Table 2). Identified
optimal cut-offs to detect the composite outcome largely
depended on sex but not ethnicity for UW and KURE partic-
ipants (< 19.0 W/kg and < 19.1 W/kg for UW and KURE
women; < 22.6 W/kg and < 24.7 W/kg for UW and KURE
men). When Caucasian and Asian cohorts were combined,
the optimal binary cut-off for lowweight-corrected jump pow-
er was set at < 19.0 W/kg (sensitivity 0.72, specificity 0.67,
AUC at point 0.69) in women and < 23.8 W/kg (sensitivity
Table 1 Clinical characteristics






Age, years 74.9 ± 3.9 75.3 ± 3.7 0.372
Women, n (%) 130 (68.4) 65 (68.4) 0.999
BMI, kg/m2 23.8 ± 3.1 26.7 ± 4.9 <0.001
Maximum jump height, cm 17.9 ± 8.6 18.4 ± 6.7 0.628
Weight-corrected jump power, W/kg (men) 26.9 ± 4.7 24.8 ± 4.6 0.050
Weight-corrected jump power, W/kg (women) 19.7 ± 4.5 18.6 ± 4.6 0.096
Sarcopenia (EWGSOP2), n (%) 14 (7.4) 7 (7.4) 0.999
Dysmobility syndrome, n (%) 53 (27.9) 30 (31.6) 0.519
Composite outcome (presence of either sarcopenia or dysmobility
syndrome), n (%)
54 (28.4) 31 (32.6) 0.650
Low grip strengtha, n (%) 20 (10.5) 17 (17.9) 0.081
Slow gait speedb, n (%) 83 (43.7) 18 (18.9) <0.001
High fat massc, n (%) 37 (19.5) 44 (46.3) <0.001
Low lean massd, n (%) 49 (25.8) 19 (18.9) 0.199
Falls in previous year, n (%) 51 (26.8) 33 (34.7) 0.168
Osteoporosise, n (%) 80 (42.1) 25 (26.3) 0.009
Abbreviations: KURE, Korean Urban Rural Elderly cohort (Koreans); UW, University of Wisconsin-Madison
cohort (Caucasians); AWGS, AsianWorking Group for Sarcopenia; EWGSOP2, revised sarcopenia definition by
European Working Group on Sarcopenia in Older People
a Grip strength <27 kg in men and < 16 kg in women according to EWGSOP2 sarcopenia definition
bGait speed <1.0 m/s
c Percent body fat >30% in men and > 40% in women
dDual-energy x-ray absorptiometry (DXA)-based appendicular lean mass (ALM)/height2 < 7.26 kg/m2 (men)
and < 5.45 kg/m2 women in the UW cohort according to the dysmobility syndrome definition; BIA-based ALM/
height2 < 7.0 kg/m2 (men) and < 5.7 kg/m2 women in the KURE cohort according to the Asian Working Group
for Sarcopenia definition
e Bone mineral density T-score − 2.5 or lower at lumbar spine, femoral neck, or total hip measured by DXA
487Osteoporos Int (2021) 32:483–493
0.73, specificity 0.81, AUC at point 0.77) in men. The sensi-
tivity and specificity of the cut-offs in overall participants
were 0.68 and 0.73. When the predicted probability of the
composite outcome estimated from logistic regression model
(y axis) was plotted against weight-corrected jump power (x-
axis), the proposed cut-offs aligned near the inflection point
for the steeper increase of probability of the presence of com-
posite outcome in UW and KURE men and women (Fig. 2).
Similar results were observed for sarcopenia alone or
dysmobility syndrome alone as outcomes (Supplementary
Fig. 6).
Odds ratio of sarcopenia or dysmobility syndrome
according to low jump power
Participants with low weight-corrected jump power (< 19.0 W/
kg inwomen; < 23.8W/kg inmen) had 5.8-fold elevated odds of
having either sarcopenia or dysmobility syndrome (composite
endpoint) compared with those with normal to high jump power
(crude odds ratio [OR] 5.80, 95%CI 3.34–10.09, p < 0.001). The
association between low jump power and the composite of
sarcopenia or dysmobility syndrome remained robust after ad-
justment for age, sex, height, and ethnic groups (UWvs.KURE)(
adjusted OR [aOR] 4.67, 95% CI 2.60–8.38, p < 0.001), with
similar results for sarcopenia (aOR 4.07, 95% CI 1.45–11.41,
p = 0.008) alone or dysmobility syndrome alone (aOR 4.32,
95% CI 2.40–7.80, p < 0.001). See Table 3. When weight-
corrected jump power was entered into themultiple logistic mod-
el as a continuous variable, 1-W/kg decrease of jump power was
associated with 20% elevated odds of presence of sarcopenia or
dysmobility syndrome (composite outcome) independent of co-
variates (aOR 1.20, 95% CI 1.11–1.28, p< 0.001).
Additive discriminatory value of low jump power for
sarcopenia or dysmobility syndrome
In ROC analyses , weight-corrected jump power alone
yielded modest discriminatory performance for the
composite of sarcopenia or dysmobility syndrome
(AUC 0.77), which was comparable with that of
a model including age, sex, height, and ethnic groups
(model 1 in Fig. 3; AUC 0.72 vs. 0.77, p = 0.123).
Jump height yielded a similar AUC to jump power
(Supplementary Fig. 7, AUC 0.76 vs. 0.77, p = 0.658).
Adding low jump power to model 1 significantly im-
proved discriminatory performance for the composite
of sarcopenia or dysmobility syndrome (AUC 0.72 to
0.79, p = 0.004).
Discussion
This analysis of age- and sex-matched Asian and Caucasian
older adults indicates that jump power values of < 19.0 W/kg
in women and < 23.8 W/kg in men can be utilized as an inter-
national threshold for identifying individuals with sarcopenia or
dysmobility syndrome. Low jump power defined by these cut-
offs was an independent risk factor for the composite outcome
with an odds ratio of 4.67, which improved the discrimination
for individuals with sarcopenia or dysmobility syndrome when
considered together with age, sex, height, and ethnicity.
These findings are well aligned with previous reports
showing that jump power improves discrimination be-
tween those with or without dysmobility syndrome in
the KURE cohort [24]. In an analysis of US cohorts,
Siglinsky and colleagues proposed jump power cut-offs
to be in the range of 15–17 W/kg depending on which
sarcopenia definition was used. Those without sarcopenia
had values of approximately 20 W/kg [30]. However, cut-
offs were not separated by sex. Singh and colleagues also
found that individuals with sarcopenia had lower jump
power compared with those without, even though they
used a different method for measuring jump power [31].
Intriguingly, the distribution of jump power in these var-
ious cohorts was similar to the range of jump power in
our study. [19–21, 23–25, 28–31, 34, 35]. Although
Table 2 Proposed cut-offs of
jump power for identifying indi-
viduals with composite outcome
as presence of either sarcopenia
(EWGSOP2) or dysmobility
syndrome
Groups Cut-off*, W/kg Sensitivity Specificity AUC at point
UW women (n = 65) < 19.0 0.81 0.74 0.78
UW men (n = 30) < 22.6 0.75 0.73 0.74
KURE women (n = 130) < 19.1 0.66 0.65 0.66
KURE men (n = 60) < 24.7 0.86 0.79 0.82
Women (UW and KURE; n = 195) < 19.0 0.72 0.67 0.69
Men (UW and KURE; n = 90) < 23.8 0.73 0.81 0.77
*Diagnostic cut-offs were determined using Liu methods in each group. Identical results were obtained when
Youden index was applied to find cut-offs in each group
KURE, Korean Urban Rural Elderly cohort (Koreans); UW, University of Wisconsin-Madison cohort
(Caucasians); AUC, area under the receiver-operating characteristics curve
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participants were not separated into those with sarcopenia
or without in these studies, the similarity in the range of
jump power suggests that our results might be
transferable to other populations. However, the proposed
cut-offs need to be validated in additional cohorts and
ethnicities other than Asian and Caucasian.
Fig. 2 Predicted probability of
the composite outcome, defined
as presence of either sarcopenia or
dysmobility syndrome, according
to weight-corrected jump power.
Sarcopenia was defined using
EWGSOP2 guideline. Probability
of composite outcome was esti-
mated from logistic regression
model, which included weight-
corrected jump power, cohort
types, and the interaction term
between two variables as inde-
pendent variables. *Composite
outcome: presence of either
sarcopenia or dysmobility
syndrome
Table 3 Association of low jump
power defined by proposed
international threshold with
sarcopenia, dysmobility




Outcomes Crude OR (95%CI) p value Adjusted OR (95%CI)* p value
Composite outcome† 5.80 (3.34–10.09) < 0.001 4.67 (2.60–8.38) < 0.001
Sarcopenia (by EWGSOP2
definition)
4.30 (1.61–11.45) 0.003 4.07 (1.45–11.41) 0.008
Dysmobility syndrome 5.41 (3.11–9.40) < 0.001 4.32 (2.40–7.80) < 0.001
*Adjusted for age, sex, height, and ethnicity (UW vs. KURE)
†Composite outcome: either presence of sarcopenia (EWGSOP2) or dysmobility syndrome
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As there is no agreement on one single sarcopenia defini-
tion and several cut-offs for various muscle and physical func-
tion tests exist, we deliberately chose the establishment of cut-
offs for jump power that could be generalizable not only in-
ternationally to different populations but also for individuals
with or without any sarcopenia or dysmobility syndrome as
the primary aim of this study. To do so, we decided that our
endpoint would combine different ways to define poor mus-
culoskeletal health. First, the sarcopenia was defined accord-
ing to EWGSOP2 algorithm. It is important to note that the
recent 2018 EWGSOP2 definition differs significantly from
the 2010 EWGSOP definition leading to different sarcopenia
prevalence in the same population [7]. In our view, the 2018
EWGSOP2 definition has clear advantages because “probable
sarcopenia” can now be diagnosed without measuring lean
mass, a clinically very important change. The previous limi-
tation to depend on lean mass as a parameter to define poor
musculoskeletal health but not on function was also one rea-
son for the development of dysmobility syndrome. In
dysmobility syndrome, low leanmass is only one of six equal-
ly weighted factors included in the definition. Dysmobility
syndrome not only balances the importance of low lean mass
but it also includes other organ systems that play a vital role in
musculoskeletal health, namely, the bone, fat, and indirectly
(through the prevalence of falls) the nervous system [9–12,
42]. The criteria and cut-offs were chosen based on a thorough
literature review but these need to be adjusted as more data
becomes available [9–12, 24, 42, 43]. Because dysmobility
syndrome approaches musculoskeletal health differently, we
felt that using a composite outcome of either dysmobility syn-
drome or sarcopenia in two cohorts with different ethnicities
would increase the likelihood of finding cut-offs that can be
applied to different populations and different definitions of
musculoskeletal health. Using such a composite outcome is
further supported by the fact that the association with de-
creased mobility and increased falls, fractures, and mortality
is similar between the two entities [1, 3, 5, 7, 12–16, 42, 44].
Other authors have used other terms and parameters to de-
scribe syndromes of impaired muscle, low bone mass, and
obesity, including osteosarcopenic obesity or locomotive syn-
drome [43–45]. Future studies are needed to examine whether
the proposed jump power cut-offs can also be applied to these
syndromes.
The jump power measurement has advantages as a test with
good reproducibility, good correlation with other methods to
measure physical function andmusclemass, little or no ceiling
effect, and good safety [4, 20, 21, 28, 29]. Relatively weak
correlations between hand grip strength and jump power
shown in prior studies may indicate that jump power has an
advantage over hand grip strength as a parameter for lower
extremity function, a clinically relevant region due to the as-
sociation with falls and hip fractures in older adults [46].
However, some limitations need to be pointed out. Jump pow-
er is measured on a force plate, which limits the portability of
the methodwith additional cost. However, research is ongoing
whether jump power can be assessed without using a force
plate [31, 47, 48]. Another limitation is the current scarcity of
studies that have prospectively examined the direct relation-
ship of low jump power with health outcomes such as falls,
fractures, immobility, decreased daily activity, or mortality,
although cross-sectional studies robustly support the associa-
tion between lower jump power or inability to jump with
worse ADLs and more falls [23, 28]. Some large, well-
established musculoskeletal cohorts, such as the MrOS study,
Fig. 3 Improved discriminatory
performance for the composite
outcome when low jump power
was added to model 1 including
age, sex, height, and ethnicity.
The composite outcome was




jump power alone was similar to
those of model 1
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have included jump power in their assessment recently, and
prospective data should be available in the near future. Our
hope is that the proposition of jump power cut-offs will en-
courage other groups to start using jump power in their re-
search to validate our results and examine the relationship of
jump power and health outcomes. In our prior work, we found
that individuals who failed or refused to jump due to various
reasons had elevated odds of dysmobility syndrome in
community-dwelling Korean older adults [24]. Based on these
findings, it would be reasonable to consider groups who had
jump power lower than the identified thresholds or those who
failed (or refused) to jump as high risk groups. This needs to
be validated in further studies.
Creating an age- and gender-matched dataset out of two
cohorts of community-dwelling older adults from two differ-
ent ethnic backgrounds enables us to reduce confounding
from variables other than ethnicity but also led to a smaller
sample size mainly due to the age gap between two cohorts.
As already pointed out, this study did not include other eth-
nicities, and as such, further studies are necessary to show that
these cut-offs are truly “international.” However, we feel that
it is a clear strength to have examined individuals from the two
large ethnic groups, Caucasian and Asian. Because there cur-
rently is no consensus of the optimal cut-off for low lean mass
among different ethnicities and the methodology for measur-
ing lean mass was different in two ethnic cohorts, regional
definitions were applied per EWGSOP2 by race and the
ALM acquisition methodology used to derive respective cut-
offs [3, 35, 39, 40]. We used the DXA-based EWGSOP 2018
appendicular lean mass cut-offs for the Caucasian (UW) co-
horts and the BIA-based AWGS cut-offs to define low lean
mass for the Asian cohort (KURE) based on Asian normative
references [3, 40]. Despite the differences in lean mass assess-
ment between two cohorts, we observed similar prevalence of
sarcopenia, dysmobility syndrome, and composite outcome
between age-matched Caucasian and Asian cohorts in this
study. Another point that needs to be noted is the differences
in body composition between the Korean-Asian and US-
Caucasian population. High fat mass was more prevalent in
the Caucasian individuals, whereas low lean mass was more
common in the Asian cohort. However, the distribution of
their muscle function, particularly muscle power, was similar
regardless of the differences in body composition. To us, this
is an advantage of a score-based diagnosis rather than an ap-
proach where the diagnosis of sarcopenia solely relies on the
presence of low lean mass. Which factors should be included
in such a score-based approach to diagnose poor musculoskel-
etal health is still up for discussion. The dysmobility syndrome
approach is a simple and powerful but can certainly be im-
proved further. The results from this study suggest that one
possibility would be the inclusion of jump power in the defi-
nition of dysmobility syndrome or sarcopenia, which merits
further validation.
Conclusion
The results of this combined analysis of older community-
dwelling adults of Asian and Caucasian ethnicities indicate
that it is possible to use sex-stratified jump power cut-offs to
discriminate between individuals with either sarcopenia or
dysmobility syndrome and without. Low jump power defined
by the proposed cut-off of 19.0 W/kg for females and 23.8W/
kg for males led to 4.7-fold elevated odds for the composite
outcome of either sarcopenia or dysmobility syndrome with
improved discriminatory performance, independent of age,
sex, height, and ethnicity. Further studies are needed to vali-
date the proposed international cut-offs in other ethnicities
with predictive value for falls, fractures, and mortality.
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